Biohaven Ltd. (BHVN) stock
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
$12.39−1.26 (-9.23%)
Close on Nov 20, 2026Market cap $1.87BP/E –Yield –
Biohaven net income
Net income is the profit left for shareholders after every expense, interest and tax.
Biohaven's net income for the twelve months ending Sep 30, 2026 was -$542.68M. For fiscal 2025 it was -$738.82M. The highest annual figure on record is -$118.67M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$738.82M | – |
| FY2024 | Dec 31, 2024 | -$846.42M | – |
| FY2023 | Dec 31, 2023 | -$408.17M | – |
| FY2022 | Dec 31, 2022 | -$570.28M | – |
| FY2021 | Dec 31, 2021 | -$213.80M | – |
| FY2020 | Dec 31, 2020 | -$118.67M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$129.28M | – |
| Q2 FY2026 | Jun 30, 2026 | -$137.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$130.53M | – |
| Q4 FY2025 | Dec 31, 2025 | -$145.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$173.44M | – |
| Q2 FY2025 | Jun 30, 2025 | -$198.15M | – |
| Q1 FY2025 | Mar 31, 2025 | -$221.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$186.84M | – |
| Q3 FY2024 | Sep 30, 2024 | -$160.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$319.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$179.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$144.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$102.57M | – |
| Q2 FY2023 | Jun 30, 2023 | -$90.35M | – |
| Q1 FY2023 | Mar 31, 2023 | -$70.49M | – |
| Q4 FY2022 | Dec 31, 2022 | -$201.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$68.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$203.29M | – |
| Q1 FY2022 | Mar 31, 2022 | -$97.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.89M | – |
| Q3 FY2021 | Sep 30, 2021 | -$54.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$45.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$62.12M | – |
See a number that looks wrong?